CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
teriparatide +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01292252
NCT01292252Phase 4Completed
CompareCT.gov

Assessment of the Efficacy of Forteo (Teriparatide) in Patients Undergoing Posterolateral Lumbar Spinal Fusion

Shane Burch·interventional·Posted Feb 9, 2011·Updated May 3, 2021

In Brief

A Phase 4 clinical trial evaluating teriparatide and Placebo for Lumbar Spondylosis and 2 related conditions. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effects of 12 weeks of daily treatment with teriparatide on spine fusion in adult patients who are undergoing multi-level posterolateral spine fusion surgery for degenerative conditions of the lumbar spine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLumbar Spondylosis, Lumbar Spondylolisthesis, Adult Degenerative Lumbar Scoliosis
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 9, 2011
Enrollment StartAug 1, 2011
Primary CompletionDec 1, 2015
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.4 years ago

Interventions

teriparatidebiological

Teriparatide 20 ug subcutaneous injection daily for 12 weeks

Placebobiological

Saline solution